Enrique M. Ocio

13.7k total citations
206 papers, 5.2k citations indexed

About

Enrique M. Ocio is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Enrique M. Ocio has authored 206 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Hematology, 112 papers in Molecular Biology and 89 papers in Oncology. Recurrent topics in Enrique M. Ocio's work include Multiple Myeloma Research and Treatments (146 papers), Protein Degradation and Inhibitors (64 papers) and Peptidase Inhibition and Analysis (45 papers). Enrique M. Ocio is often cited by papers focused on Multiple Myeloma Research and Treatments (146 papers), Protein Degradation and Inhibitors (64 papers) and Peptidase Inhibition and Analysis (45 papers). Enrique M. Ocio collaborates with scholars based in Spain, United States and France. Enrique M. Ocio's co-authors include Jesús F. San Miguel, María‐Victoria Mateos, Atanasio Pandiella, Ramón García‐Sánz, Mercedes Garayoa, Patricia Maiso, Norma C. Gutiérrez, Fermín Sánchez‐Guijo, María‐Belén Vídriales and Laura San‐Segundo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Enrique M. Ocio

200 papers receiving 5.1k citations

Peers

Countries citing papers authored by Enrique M. Ocio

Since Specialization

Citations

This map shows the geographic impact of Enrique M. Ocio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrique M. Ocio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrique M. Ocio more than expected).

Fields of papers citing papers by Enrique M. Ocio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enrique M. Ocio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrique M. Ocio. The network helps show where Enrique M. Ocio may publish in the future.

Co-authorship network of co-authors of Enrique M. Ocio

This figure shows the co-authorship network connecting the top 25 collaborators of Enrique M. Ocio. A scholar is included among the top collaborators of Enrique M. Ocio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrique M. Ocio. Enrique M. Ocio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma 2024 ·Haematologica ·Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothée Sémiond, (unknown), Paúl Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau	2
2	Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Enrique M. Ocio, (unknown), Gabriela Bustamante, (unknown), (unknown), Ernesto Pérez Persona, Verónica González‐Calle, (unknown), José-María Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, (unknown), (unknown), (unknown), Laura Rosiñol	1
3	Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma 2023 ·Blood ·Fredrik Schjesvold, Andrew Spencer, Yaël C. Cohen, Enrique M. Ocio, (unknown), Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, (unknown), Rebecca Kan, (unknown), Gina M. Trabucco, (unknown), Romain Séchaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab	3
4	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial 2020 ·Cancers ·Noemí Puig, Luís A. Corchete, (unknown), Julio Dávila, Teresa Paíno, Javier de la Rubia, Albert Oriol, Jesús Martín, Felipe de Arriba, Joan Bladé, María‐Jesús Blanchard, Verónica González‐Calle, Ramón García‐Sánz, Bruno Paiva, Juan José Lahuerta, Jesús F. San Miguel, María‐Victoria Mateos, Enrique M. Ocio	7
5	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group 2020 ·British Journal of Haematology ·Enrique M. Ocio, (unknown), Paula Rodríguez‐Otero, Joaquín Martínez‐López, (unknown), Jesús Martín, Joan Bladé, (unknown), (unknown), Aránzazu García‐Mateo, Felipe de Arriba, Ramón García‐Sánz, Javier de la Rubia, Albert Oriol, Juan José Lahuerta, Jesús F. San Miguel, María‐Victoria Mateos	14
6	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma 2017 ·Clinical Cancer Research ·Elizabeta A. Rojas, Luís A. Corchete, Laura San‐Segundo, Juan F. Martínez‐Blanch, Francisco M. Codoñer, Teresa Paíno, Noemí Puig, Ramón García‐Sánz, María‐Victoria Mateos, Enrique M. Ocio, Irena Misiewicz-Krzemińska, Norma C. Gutiérrez	28
7	A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation 2017 ·Blood ·Enrique M. Ocio, Sara Bringhen, Stefania Oliva, Paula Rodríguez‐Otero, (unknown), Corina Oprea, Vivian Wei, (unknown), Joaquín Martínez‐López	8
8	Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) 2017 ·Blood ·Xiaozhong Qian, Meletios Α. Dimopoulos, Michael Amatangelo, Chad C. Bjorklund, Katja Weisel, Enrique M. Ocio, Xin Yu, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau, Anjan Thakurta	1
9	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care 2016 ·Clinical Cancer Research ·Teresa Paíno, Antonio García-Gómez, (unknown), Laura San‐Segundo, Susana Hernández-García, (unknown), (unknown), (unknown), (unknown), Carlos Ortíz-de-Solórzano, Luís A. Corchete, Norma C. Gutiérrez, (unknown), Mercedes Garayoa, Enrique M. Ocio	43
10	OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY 2015 ·Haematologica ·Antonio Palumbo, Philippe Moreau, Meletios Α. Dimopoulos, Paolo Corradini, Michèle Cavo, Michel Delforge, Katja Weisel, Hartmut Goldschmidt, Massimiliano Petrini, Martin Kaiser, Ana Slaughter, Mathew Simcock, Jennifer Herring, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Enrique M. Ocio	1
11	THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA 2015 ·Haematologica ·Meletios Α. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michèle Cavo, Michel Delforge, Katja Weisel, Enrique M. Ocio, Francesco Di Raimondo, Albert Oriol, Mathew Simcock, Neil Miller, Ana Slaughter, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau	1
12	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy 2014 ·Molecular Cancer Therapeutics ·Xi Chen, Elena Díaz‐Rodríguez, Enrique M. Ocio, Bruno Paiva, Deborah S. Mortensen, Antonia Lopez‐Girona, Rajesh Chopra, Jesús F. San Miguel, Atanasio Pandiella	8
13	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010) 2014 ·Blood ·Katja Weisel, Meletios Α. Dimopoulos, Michèle Cavo, Enrique M. Ocio, Antonio Palumbo, Paolo Corradini, Michel Delforge, Albert Oriol, H. Goldschmidt, Concetta Conticello, Angelo Vacca, Markus Hansson, Neil Miller, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau	9
14	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor 2013 ·Clinical Cancer Research ·Stela Álvarez-Fernández, (unknown), (unknown), Sara Zaknoen, Enrique M. Ocio, Jesús F. San Miguel, Francis Burrows, Azucena Esparís‐Ogando, Atanasio Pandiella	43
15	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile 2013 ·Blood ·Bruno Paiva, Teresa Paíno, (unknown), Mercedes Garayoa, Laura San‐Segundo, (unknown), Inês Mota, (unknown), Paloma Bárcena, Irene Aires‐Mejía, Luís A. Corchete, Cristina Jiménez, Ramón García‐Sánz, Norma C. Gutiérrez, Enrique M. Ocio, María‐Victoria Mateos, María‐Belén Vídriales, Alberto Órfão, Jesús F. San Miguel	115
16	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis 2011 ·Blood ·Bruno Paiva, María‐Belén Vídriales, José J. Pérez, (unknown), Ramón García‐Sánz, Enrique M. Ocio, Natalia de las Heras, Rebeca Cuello, Alfonso García de Coca, Emilia Pardal, José María Alonso, Magdalena Sierra, Abelardo Bárez, José‐Ángel Hernández‐Rivas, (unknown), Josefina Galende, María‐Victoria Mateos, Jesús F. San Miguel	46
17	International prognostic scoring system for Waldenström macroglobulinemia 2009 ·Blood ·Pierre Morel, Alain Duhamel, Paolo G. Gobbi, Meletios Α. Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, John Crowley, Enrique M. Ocio, Ramón García‐Sánz, Steven P. Treon, Véronique Leblond, Robert A. Kyle, Bart Barlogie, Giampaolo Merlini	228
18	Biological value of housefly larvae estimated in chickens by the crude protein method. 1980 ·Enrique M. Ocio, (unknown), J. Rey, (unknown)	1
19	Utilization of seeds of Vicia ervilla in the feeding of chickens. 2. Effects of the inclusion of high levels of seed for finishing chickens. 1980 ·Enrique M. Ocio, (unknown), J. Treviño, A. Brenes	1
20	Utilization of seeds of Vicia ervilla in the feeding of chickens. 1. Effects of including high levels of seed in starter diets. 1980 ·Enrique M. Ocio, (unknown), J. Treviño, A. Brenes	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact